Aerovate Therapeutics Inc expected to post a loss of 82 cents a share - Earnings Preview

Jade Biosciences

09/08/2024 18:45

* Aerovate Therapeutics Inc  AVTE.OQ   AVTE.O  is expected
to show
no change in quarterly revenue when it reports  results on
August 12 (estimated) for the period ending June 30 2024
    * 
    * ​LSEG's mean analyst estimate for Aerovate Therapeutics
Inc is
for a loss of 82 cents per share. 
    * The current average analyst rating on the shares is "hold"
and
the breakdown of recommendations is no "strong buy" or "buy," 6
"hold" and no "sell" or "strong sell."  
    * The mean earnings estimate of analysts was unchanged in
the last
three months. ​
    * Wall Street's median 12-month price target for Aerovate
Therapeutics Inc is $2.00​, above​ its last closing price
of $1.70. ​​​

Previous quarterly performance (using preferred earnings measure
in US dollars). ​
 QUARTER       STARMINESM  LSEG IBES  ACTUAL    BEAT,   SURPRI
 ENDING        ARTESTIMAT  ESTIMATE             MET,    SE %
               E®                               MISSED  
 Mar. 31 2024  -0.77       -0.76      -0.83     Missed  -8.5
 Jan. 1 2024   -0.71       -0.71      -0.74     Missed  -4.6
 Sep. 30 2023  -0.70       -0.69      -0.71     Missed  -2.7​
 Jun. 30 2023  -0.70       -0.60      -0.76     Missed  -9.2
 ​​Jan.        -0.61       -0.60      -0.67     Missed  -11.7
 1 0001                                                 
 Jan. 1 0001   -0.71       -0.62      -0.61     Beat    1.3​
 Jan. 1 0001   -0.50       -0.50      -0.56     Missed  -12.4
 Jan. 1 0001   -0.46       -0.45      -0.49     Missed  -7.8
 This summary was machine generated August 9 at 17:45 GMT.  All
figures in US dollars unless otherwise stated. (For questions
concerning the data in this report, contact
Estimates.Support@lseg.com. For any other questions or feedback,
contact RefinitivNewsSupport@thomsonreuters.com)